PHARMACOLOGIC REDUCTION OF ALCOHOL CONSUMPTION IN ALCOHOLIC PATIENTS

最近的研究表明，酒精消费是由几个因素调节的。 相互作用的神经递质，包括多巴胺和血清素 系统. 在随机双盲设计中，慢性酒精中毒 门诊患者将接受左旋多巴或L-5-羟色氨酸，两者都与 外周脱羧酶抑制剂卡比多巴或安慰剂治疗1年 期 在这一年里，酒精消费，肝功能，渴望 酒精，精神状态，心理社会功能，以及遵守 将定期对药物进行评估。 被带进 研究后3个月和1年，将进行以下程序 用于测量药物作用：（1）行为评价;（2） 测定药物、单胺、激素和 血液和脑脊液中的肽;（3）心脏的直立性改变 心率、血压和血浆去甲肾上腺素浓度;以及（4） 评估血浆加压素对盐水输注的反应。 变化 酒精消费将与生物化学和行为有关 参数

Recent studies indicate that alcohol consumption is regulated by several interacting neurotransmitters, including the dopamine and serotonin systems. In a randomized double-blind design, chronic alcoholic outpatients will receive L-DOPA or L-5-hydroxytryptophan, both with the peripheral decarboxylase inhibitor carbidopa or placebo for a 1-year period. During this year, alcohol consumption, liver function, craving for alcohol, mental status, psychosocial functioning, and compliance with medication will be assessed at regular intervals. Prior to entry into the study, after 3 months, and at 1 year, the following procedures will be conducted to measure drug effects: (1) behavioral evaluation; (2) determination of concentrations of drugs, monoamines, hormones, and peptides in blood and cerebrospinal fluid; (3) orthostatic changes in heart rate, blood pressure, and plasma norepinephrine concentrations; and (4) assessment of plasma vasopressin response to saline infusion. Changes in alcohol consumption will be related to biochemical and behavioral parameters.